Whether this is a childhood diagnosis being managed for the first time with medical aid cover, or a moderate-to-severe adult presentation requiring escalation to biologic therapy, this guide answers the key coverage questions.
Does My Medical Aid Have to Cover This?
Atopic dermatitis is not a CDL condition. There is no statutory minimum treatment benefit. Cover is funded through the standard medicine benefit (MSA) and, for biologics, through exceptional-needs authorisation.
What your scheme is expected to fund: - Emollients and topical corticosteroids — standard medicine benefit / MSA - Specialist consultations (dermatologist) — specialist benefit - Systemic immunosuppressants (cyclosporine, methotrexate) — standard medicine benefit / MSA - Biologics (dupilumab, tralokinumab) — exceptional-needs authorisation required
Starting Treatment: What Most Patients Need
The majority of AD patients (mild-to-moderate disease) are managed effectively with the following, all accessible through standard benefits:
- Daily emollient applied liberally across all skin — this is the foundation; no prescription required but large quantities are needed. Monthly cost: R300–R600 depending on body surface area and frequency.
- Topical corticosteroids for active flares — prescribed by GP or dermatologist. Inexpensive. Available at all pharmacies.
- Avoiding known triggers — soap avoidance, dust mite reduction, temperature management. No cost.
If topical therapy is controlling flares adequately and you are not seeking to escalate treatment, your annual cost is low and the MSA is adequate for most plans.
When to See a Dermatologist
See a dermatologist if: - Topical therapy is not controlling flares adequately after 4–6 weeks - Flares are occurring more than 2–3 times per year despite good compliance - The disease is affecting sleep significantly every week - Skin infections (impetigo, widespread Staphylococcus) are recurrent - You are considering biological therapy
A dermatologist consultation typically costs R800–R1,400 per visit. Covered through the specialist consultation benefit; confirm whether a referral letter is required by your scheme for the specialist benefit rate to apply.
The Step-Therapy Requirement for Biologics
Dupilumab is transformative for moderate-to-severe AD. Most schemes require documented failure of prior therapies before approving it. The typical step-therapy pathway:
- Adequate trial of mid-to-high potency topical corticosteroids — documented failure or intolerance
- Topical calcineurin inhibitor (tacrolimus/pimecrolimus) — documented outcome
- Systemic therapy (cyclosporine or methotrexate) — documented failure or intolerance (this step is often required)
- Dupilumab exceptional-needs application with all prior therapy documented
If you are at step 3 and cyclosporine has not yet been trialled, your dermatologist may recommend a 3–6 month course specifically to document its outcome before proceeding to the biologic application. This is a clinical and administrative requirement, not just a cost-saving measure for the scheme.
Getting Dupilumab Funded
If your dermatologist recommends dupilumab, the application process:
- Your dermatologist submits an exceptional-needs motivation with: EASI/IGA score, prior therapy history, clinical photographs
- The scheme's medical advisor reviews and approves, declines, or requests further information
- Timeline: typically 2–6 weeks; request expedited review if disease is severely affecting quality of life or sleep
- If approved: dupilumab is funded from the exceptional-needs/biologic benefit. Monthly cost: ~R14,000.
- If declined: see V3 (Crisis article) for appeal pathway
Managing Flares During Exceptional-Needs Approval Process
The exceptional-needs application takes weeks. During this time, disease continues. Strategies:
- Prednisolone short course (oral steroid) can be used for severe, acute flares during the waiting period — inexpensive; discuss with dermatologist
- Continue or escalate topical therapy as directed
- Ask your dermatologist whether a compassionate use supply or sample product is available through the pharmaceutical company while the application is pending
Children with Severe Atopic Dermatitis
Dupilumab is approved from age 6 months in the EU. SA SAHPRA approval for paediatric age groups requires verification. For children under 12 with severe AD, the biologic approval pathway may differ. Ask your paediatric dermatologist specifically about the age-group approval status in SA.
Checklist
| Action | Priority |
|---|---|
| Start daily emollient if not already using | Immediately |
| Confirm topical steroid potency is appropriate for location | At next appointment |
| See dermatologist if flares are not controlled | This week |
| Document prior therapy outcomes (for biologic step-therapy) | Ongoing |
| Begin dupilumab exceptional-needs application if indicated | Per dermatologist |
| Confirm specialist benefit for quarterly dermatologist review | This week |
Talk to Eldon
Get help understanding your plan options →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).
Skin Care Routine: The Daily Cost
A consistent daily skin care routine is the foundation of AD management and reduces flare frequency. For moderate-to-severe AD, the daily product cost can be substantial:
- Emollient: Apply generously twice daily across all skin, not just affected areas. A 500g tub may last 1–2 weeks for widespread disease. Monthly emollient cost: R300–R700. These products are not glamorous but they are the single most important intervention in reducing flare frequency.
- Soap substitute: Soap irritates AD skin. Use an emollient-based soap substitute or a gentle syndet cleanser for bathing. Cost: R150–R300/month.
Ask your scheme whether emollient prescriptions are covered under the chronic medicine benefit. Some plans cover prescribed emollients as a medicine benefit line item; others treat them as cosmetic products and do not cover them. If your scheme covers prescribed emollients, get them on prescription from your dermatologist and claim them through the benefit.
Wet Wrap Therapy for Acute Flares
Wet wrap therapy (damp inner layer + dry outer layer applied over emollient and topical corticosteroids) is a short-term technique for managing acute severe flares in children. It is not a hospital admission — it is a home technique taught by a dermatologist or specialist nurse. Ask your dermatologist whether wet wrap therapy is appropriate for your child's acute flares and request the technique instruction at the next appointment.